Cargando…

Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity

Evaluation of the mutational status of KRAS is a crucial step for the correct therapeutic approach in treating advanced colorectal cancer as the identification of wild-type KRAS tumors leads to more specific and less toxic treatments for patients. Although several studies have highlighted the differ...

Descripción completa

Detalles Bibliográficos
Autores principales:	IMPROTA, GIUSEPPINA, ZUPA, ANGELA, POSSIDENTE, LUCIANA, TARTARONE, ALFREDO, PEDICINI, PIERNICOLA, NAPPI, ANTONIO, MOLINARI, SERGIO, FRAGGETTA, FILIPPO, VITA, GIULIA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2013
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3678636/ https://www.ncbi.nlm.nih.gov/pubmed/23761841 http://dx.doi.org/10.3892/ol.2013.1255

Ejemplares similares

Coexistence of KRAS and BRAF Mutations in Colorectal Cancer: A Case Report Supporting The Concept of Tumoral Heterogeneity
por: Larki, Pegah, et al.
Publicado: (2017)

Modelling the correlation between EGFr expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors
por: Pedicini, Piernicola, et al.
Publicado: (2012)

Local tumor control probability to evaluate an applicator‐guided volumetric‐modulated arc therapy solution as alternative of 3D brachytherapy for the treatment of the vaginal vault in patients affected by gynecological cancer
por: Pedicini, Piernicola, et al.
Publicado: (2013)

New developments in the management of advanced melanoma – role of pembrolizumab
por: Improta, Giuseppina, et al.
Publicado: (2015)

Correction: modelling the correlation between EGFr expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors
por: Pedicini, Piernicola, et al.
Publicado: (2012)

Correlation between egfr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma
por: Pedicini, Piernicola, et al.
Publicado: (2012)

Biological insights into BRAF(V600) mutations in melanoma patient: Not mere therapeutic targets
por: Improta, Giuseppina, et al.
Publicado: (2013)

Oral malignant melanoma: A report of two cases with BRAF molecular analysis
por: SOMA, PIER FRANCESCO, et al.
Publicado: (2014)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

Different oncological features of colorectal cancer codon-specific KRAS mutations: Not codon 13 but codon 12 have prognostic value
por: Ahn, Hong-Min, et al.
Publicado: (2023)

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
por: Loupakis, F, et al.
Publicado: (2009)

Diagnostic Consideration for Sinonasal Wegener's Granulomatosis Clinically Mistaken for Carcinoma
por: La Rosa, Cristina, et al.
Publicado: (2013)

A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients
por: Rossi, Elisabetta, et al.
Publicado: (2021)

KRAS Codon 12 and 13 Mutations in Gastric Cancer in the Northeast Iran
por: Ayatollahi, Hossein, et al.
Publicado: (2018)

Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
por: Ali, Moiez, et al.
Publicado: (2017)

Coexistence of MSI with KRAS mutation is associated with worse prognosis in colorectal cancer
por: Hu, Jing, et al.
Publicado: (2016)

Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review
por: Imamura, Yu, et al.
Publicado: (2014)

Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages
por: Li, Wenbin, et al.
Publicado: (2015)

The importance both of early diagnosis and smoking cessation in the battle against lung cancer
por: Tartarone, Alfredo
Publicado: (2020)

Potential Role of Tumor-Derived Exosomes in Non-Small-Cell Lung Cancer in the Era of Immunotherapy
por: Tartarone, Alfredo, et al.
Publicado: (2022)

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
por: van de Haar, Joris, et al.
Publicado: (2023)

KRAS exon 2 codon 13 mutation is associated with a better prognosis than codon 12 mutation following lung metastasectomy in colorectal cancer
por: Renaud, Stéphane, et al.
Publicado: (2016)

Heterogeneity of KRAS Mutation Status in Rectal Cancer
por: Jo, Peter, et al.
Publicado: (2016)

Current Treatment Approaches for Thymic Epithelial Tumors
por: Tartarone, Alfredo, et al.
Publicado: (2023)

FLAG assay as a novel method for real-time signal generation during PCR: application to detection and genotyping of KRAS codon 12 mutations
por: Amicarelli, Giulia, et al.
Publicado: (2007)

KRAS codon 12 mutations characterize a subset of de novo proliferating “metaplastic” Warthin tumors
por: Agaimy, Abbas, et al.
Publicado: (2023)

Cardiovascular risk of smoking and benefits of smoking cessation
por: Gallucci, Giuseppina, et al.
Publicado: (2020)

iCodon customizes gene expression based on the codon composition
por: Diez, Michay, et al.
Publicado: (2022)

COVID-19 and cancer care: what do international guidelines say?
por: Tartarone, Alfredo, et al.
Publicado: (2020)

Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib
por: Zhu, You-Cai, et al.
Publicado: (2019)

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer
por: Jänne, P A, et al.
Publicado: (2015)

Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer
por: Jones, Robert P, et al.
Publicado: (2017)

Clinical-grade Computational Pathology: Alea Iacta Est
por: Fraggetta, Filippo
Publicado: (2019)

[F-18] FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patients
por: Nappi, Antonio, et al.
Publicado: (2015)

Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective
por: Malapelle, Umberto, et al.
Publicado: (2012)

Coexistence of two missense mutations in the KRAS gene in adenocarcinoma of the lung: a possible indicator of poor prognosis
por: Spinelli, Manuela, et al.
Publicado: (2022)

Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas
por: Rehkaemper, Jan, et al.
Publicado: (2020)

Spatial heterogeneity of KRAS mutations in colorectal cancers in northern France
por: Turpin, Anthony, et al.
Publicado: (2019)

Resource competition and coexistence in heterogeneous metacommunities: many-species coexistence is unlikely to be facilitated by spatial variation in resources
por: Schoolmaster, Donald R.
Publicado: (2013)

Analysis of KRAS Mutations of Exon 2 Codons 12 and 13 by SNaPshot Analysis in Comparison to Common DNA Sequencing
por: Zinsky, Rica, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_67r0mjd3op8s2dq9gjab259tsg